VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AXGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AXGNAxoGen, Inc.
$56.95$3.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAXGNFinancials

AxoGen, Inc. (AXGN) Income Statement

30Y historyFree accessUpdated daily

Revenue grew 26.2% year over year to $75.8M in 2026Q3 with gross margin near 74.8%, yet operating margin of only 1.3% and net margin of 3.1% indicate that SG&A spending of $46.8M still absorbs most of the gross profit.

Income StatementBalance SheetCash FlowRatios

AXGN Income Statement

Annual statement

AXGN Income Statement

AxoGen, Inc. (AXGN) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Jun'01Jun'00Jun'99Jun'98Jun'97Jun'96
Sales/Revenue266.93M225.21M187.34M159.01M138.58M127.36M112.3M106.71M83.94M60.43M41.11M27.33M16.82M10.95M7.69M4.85M91.27K24.91M72.71K100.43K126.66K443.35K1.06M7.24M6.85M15.93M14.6M12.3M12.9M12.3M13.1M
Revenue Growth %24.32%20.21%17.81%14.74%8.81%13.41%5.24%27.13%38.91%47%50.41%62.52%53.62%42.33%58.61%5213.15%-99.63%34160.81%-27.6%-20.71%-71.43%-58.37%-85.28%5.62%-56.98%9.13%18.67%-4.65%4.88%-6.11%-7.09%
Cost of Goods Sold68.92M57.85M45.36M37.14M29.77M22.93M21.58M17.35M12.92M9.31M6.47M4.85M3.44M2.44M1.96M2.43M00000005.5M5.21M10.51M8.57M7.3M8.4M6.9M7M
COGS % of Revenue-25.69%24.21%23.36%21.49%18.01%19.22%16.26%15.4%15.41%15.73%17.74%20.47%22.29%25.51%50.04%-------75.93%76.07%65.96%58.69%59.35%65.12%56.1%53.44%
Gross Profit198M167.35M141.98M121.87M108.81M104.43M90.72M89.36M71.01M51.11M34.64M22.48M13.38M8.51M5.73M2.42M91.27K24.91M72.71K100.43K126.66K443.35K1.06M1.74M1.64M5.42M6.03M5M4.5M5.4M6.1M
Gross Margin %74.18%74.31%75.79%76.64%78.51%81.99%80.78%83.74%84.6%84.59%84.27%82.26%79.53%77.71%74.49%49.96%100%100%100%100%100%100%100%24.07%23.93%34.04%41.31%40.65%34.88%43.9%46.56%
Gross Profit Growth %-17.87%16.5%12%4.2%15.11%1.52%25.84%38.93%47.56%54.08%68.09%57.22%48.48%136.48%2554.59%-99.63%34160.81%-27.6%-20.71%-71.43%-58.37%-38.85%6.22%-69.76%-10.06%20.58%11.11%-16.67%-11.48%-7.58%
Operating Expenses211.81M175.2M145.26M143.33M138.52M129.84M113.9M120.77M91.51M59.07M42.77M31.75M23.18M18.1M13.53M9.39M1.94M8.96M1.13M900.35K524.04K769.87K1.19M2.99M4.13M8.43M8.92M6.8M4.9M5.3M6.7M
OpEx % of Revenue-77.8%77.54%90.14%99.95%101.95%101.43%113.17%109.03%97.75%104.04%116.17%137.81%165.33%175.93%193.66%2125.27%35.95%1553.41%896.49%413.74%173.65%111.7%41.27%60.3%52.95%61.11%55.28%37.98%43.09%51.14%
Selling, General & Admin174.38M142.32M117.5M115.99M112.89M105.67M96.06M103.25M79.74M52.37M38.56M28.51M20.14M15.97M12.1M8.69M000900.35K524.04K769.87K1.19M2.51M3.64M7.33M6.92M4.7M3.1M2.8M3.7M
SG&A % of Revenue-63.19%62.72%72.95%81.46%82.97%85.53%96.76%95%86.66%93.8%104.32%119.77%145.92%157.37%179.28%---896.49%413.74%173.65%111.7%34.68%53.12%46.05%47.39%38.21%24.03%22.76%28.24%
Research & Development37.43M32.88M27.77M27.34M25.63M24.18M17.85M17.51M11.77M6.7M4.21M3.24M3.03M2.13M1.43M697.36K0000000424.46K491.51K919.79K1.09M1.2M1M1.5M1.9M
R&D % of Revenue-14.6%14.82%17.19%18.49%18.98%15.89%16.41%14.03%11.09%10.25%11.84%18.04%19.42%18.56%14.38%-------5.87%7.17%5.77%7.5%9.76%7.75%12.2%14.5%
Other Operating Expenses00000000-28K-30.77K-19.63K26.82K3.15K33.89K23.97K01.94M8.96M1.13M000052.38K0180K908.02K900K800K1M1.1M
Operating Income-13.8M-7.85M-3.29M-21.46M-29.71M-25.42M-23.18M-31.41M-20.5M-7.95M-8.13M-9.27M-9.8M-9.59M-7.8M-6.97M-1.85M15.96M-1.06M-799.92K-397.38K-326.52K-124.6K-1.25M-2.49M-3.32M-2.89M-1.8M-400K100K-600K
Operating Margin %-5.17%-3.49%-1.75%-13.5%-21.44%-19.96%-20.64%-29.43%-24.42%-13.16%-19.78%-33.91%-58.28%-87.62%-101.43%-143.7%-2025.27%64.05%-1453.41%-796.49%-313.74%-73.65%-11.7%-17.21%-36.37%-20.82%-19.8%-14.63%-3.1%0.81%-4.58%
Operating Income Growth %--138.79%84.68%27.75%-16.88%-9.64%26.19%-53.2%-157.82%2.2%12.27%5.45%-2.17%-22.95%-11.96%-276.99%-111.59%1609.83%-32.11%-101.3%-21.7%-162.05%89.99%50.03%24.84%-14.71%-60.58%-350%-500%116.67%-500%
EBITDA-4.89M344K4.55M-15.91M-24.85M-20.68M-19.72M-28.53M-19.65M-7.38M-7.69M-9.02M-9.6M-9.45M-7.49M-6.63M-1.83M15.98M-1.03M-777.65K-371.92K-306.48K87.68K-721.89K-1.87M-2.79M-1.98M-900K400K1.1M500K
EBITDA Margin %-1.83%0.15%2.43%-10%-17.93%-16.23%-17.56%-26.73%-23.41%-12.22%-18.72%-32.99%-57.09%-86.36%-97.34%-136.68%-2003.61%64.14%-1421.61%-774.31%-293.63%-69.13%8.23%-9.98%-27.24%-17.54%-13.58%-7.32%3.1%8.94%3.82%
EBITDA Growth %-142.95%-92.44%128.6%35.99%-20.21%-4.83%30.87%-45.19%-166.08%4.01%14.69%6.08%-1.57%-26.27%-12.96%-262.43%-111.44%1645.84%-32.92%-109.09%-21.35%-449.53%112.15%61.33%33.2%-40.95%-120.27%-325%-63.64%120%-37.5%
D&A (Non-Cash Add-back)8.91M8.19M7.84M5.55M4.85M4.74M3.46M2.88M851K566.6K436.49K248.97K198.89K138.33K314.83K340.68K19.77K23.01K23.12K22.27K25.46K20.04K212.28K523.27K625.14K521.28K908.02K900K800K1M1.1M
EBIT-30.15M-8M-1.76M-18.88M-28.32M-25.63M-22.73M-29.09M-21.19M-7.98M-8.15M-9.24M-9.8M-9.56M-7.78M-6.9M-4.48M15.96M-1.06M-799.92K-397.38K-326.52K-124.6K-1.62M-2.49M-7.72M-3.01M-2.89M-1.8M-400K100K
Net Interest Income-197K-7.7M-8.21M-2.83M-624K-1.36M-1.05M-40K-1.21M-2.46M-6.26M-4.12M-7.91M-5M-2.38M-2.32M-2.14M1.95K16.08K061.85K00-37.79K0000000
Interest Income2.22M00000000000000001.95K16.08K061.85K0000000000
Interest Expense2.41M7.7M8.21M2.83M624K1.36M1.05M40K1.21M2.46M6.26M4.12M7.91M5M2.38M2.32M2.14M00000037.79K131.08K-8.78M0002.2M0
Other Income/Expense-18.12M-7.85M-6.68M-254K759K-1.57M-604K2.27M-1.9M-2.49M-6.28M-4.09M-7.91M-4.96M-2.35M-2.25M2.66M1.95K16.08K50.94K61.85K00-370.27K-136.38K4.71M4.28M-7.71K1.4M500K0
Pretax Income-31.92M-15.7M-9.96M-21.72M-28.95M-26.98M-23.79M-29.14M-22.4M-10.45M-14.41M-13.36M-17.71M-14.56M-10.16M-6.9M-1.83M15.96M000-326.52K-124.6K-1.28M-2.63M1.39M-2.9M-1.7M-400K100K-600K
Pretax Margin %-11.96%-6.97%-5.32%-13.66%-20.89%-21.19%-21.18%-27.3%-26.68%-17.29%-35.06%-48.87%-105.31%-132.97%-132.04%-142.31%-1999.88%64.06%----73.65%-11.7%-17.67%-38.36%8.74%-19.86%-13.82%-3.1%0.81%-4.58%
Income Tax0000000002.49M0000-738.19K-134.58K-509.05K1.04M-16.08K-50.94K-30.2K0-1.45K3K-25.47K48K-38.93K-200K-100K4.6M-100K
Effective Tax Rate %0%0%0%0%0%0%0%0%0%-23.88%0%0%0%0%7.27%1.95%27.89%6.53%---0%1.16%-0.23%0.97%3.45%1.34%11.76%25%4600%16.67%
Net Income-31.92M-15.7M-9.96M-21.72M-28.95M-26.98M-23.79M-29.12M-22.4M-10.45M-14.41M-13.36M-17.71M-14.56M-9.42M-9.22M-1.32M15.05M-1.04M-748.98K-367.18K-530.61K2.3M-1.28M-2.6M1.34M-2.86M-1.7M-400K-2.3M-600K
Net Margin %-11.96%-6.97%-5.32%-13.66%-20.89%-21.19%-21.18%-27.29%-26.68%-17.29%-35.06%-48.87%-105.31%-132.97%-122.44%-190.11%-1442.16%60.4%-1431.3%-745.77%-289.9%-119.68%215.65%-17.71%-37.99%8.43%-19.59%-13.82%-3.1%-18.7%-4.58%
Net Income Growth %-1422.27%-57.6%54.12%24.98%-7.27%-13.45%18.32%-30.03%-114.42%27.52%-7.9%24.58%-21.66%-54.57%-2.16%-600.39%-108.75%1545.78%-38.95%-103.98%30.8%-123.1%279.18%50.75%-293.73%146.99%-68.19%-325%82.61%-283.33%-400%
Net Income (Continuing)-31.92M-15.7M-9.96M-21.72M-28.95M-26.98M-23.79M-29.14M-22.4M-10.45M-14.41M-13.36M-17.71M-14.56M-9.42M-9.22M-1.32M14.92M-1.04M-748.98K-335.53K-326.52K-123.15K-1.62M-2.6M1.34M1.34M-2.86M-1.7M-400K-2.3M
Discontinued Operations00000000000000000130K0000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)-0.52-0.34-0.23-0.51-0.69-0.65-0.60-0.74-0.60-0.31-0.47-0.51-1.00-1.08-0.85-2.49-0.313.49-0.24-0.18-0.09-0.130.57-0.32-0.660.34-0.74-0.43-0.10-0.60-0.16
EPS Growth %-1229.24%-47.83%54.9%26.09%-6.15%-8.33%18.92%-23.33%-93.55%34.04%7.84%49%7.41%-27.06%65.86%-703.23%-108.88%1554.17%-33.33%-103.39%31.92%-122.81%278.13%51.52%-294.12%145.95%-72.09%-330.43%83.35%-275%-405.93%
EPS (Basic)--0.34-0.23-0.51-0.69-0.65-0.60-0.74-0.60-0.31-0.47-0.51-1.00-1.08-0.85-2.49-0.313.51-0.24-0.18-0.09-0.130.57-0.32-0.660.34-0.74-0.43-0.10-0.60-0.16
Diluted Shares Outstanding61.53M46.05M44.26M42.88M42.08M41.22M39.97M39.23M37.13M33.32M30.7M26.08M17.72M13.5M11.09M3.7M4.31M4.31M4.27M4.17M4.15M4.13M4.12M3.97M3.96M3.93M3.89M3.95M4.01M3.86M3.8M
Basic Shares Outstanding55.16M46.05M44.26M42.88M42.08M41.22M39.97M39.23M37.13M33.32M30.7M26.08M17.72M13.5M11.09M3.7M4.31M4.29M4.27M4.17M4.15M4.13M4.01M3.97M3.96M3.91M3.89M3.95M4.01M3.84M3.8M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Top-Line Growth Holds Near Twenty Percent

According to reported quarterly figures, AXGN's revenue reached $75.8M in 2026Q3, up 26.2% year over year, with growth sustained at 23.1% to 26.6% across the most recent three quarters, suggesting durable commercial momentum.

The consistency of growth across quarters suggests demand is being driven by expanding surgical account penetration rather than a single lumpy event. Investors should note that the revenue base is still small relative to the company's cost structure, so sustaining this rate will be essential to justify the current valuation. Whether this growth reflects volume or pricing is not separable from the reported data and warrants further investigation.

Gross Margin Anchored Near Seventy-Five Percent

Based on reported figures, AXGN's gross margin has held between 71.9% and 76.6% over ten quarters, with the most recent quarter at 74.8%, indicating that the proprietary processing advantage appears structurally intact despite volume scaling.

A stable high gross margin implies the company retains meaningful pricing power and that tissue recovery yields have not deteriorated materially as volumes grew. The quarterly swings, particularly the dip to 71.9% in 2025Q1, may reflect transitional manufacturing variances rather than a structural shift. Margin durability at this level is a key pillar of the investment case, and any sustained compression would merit close scrutiny.

Operating Leverage Remains Elusive

As reported in financial statements, AXGN's operating margin moved from -16.3% in 2025Q4 to just 1.3% in 2026Q3, but remained negative in three of the last four quarters, indicating that gross profit gains are not yet translating into consistent operating leverage.

SG&A has grown roughly in line with gross profit, which suggests the commercial infrastructure is being expanded to support growth rather than absorbing it efficiently. The positive operating result in the latest quarter is encouraging but appears to be a single data point that may not yet reflect a structural inflection. Investors should monitor whether SG&A as a percentage of revenue declines meaningfully in the coming quarters.

Net Income Volatility Obscures Underlying Trend

Based on EDBL's reported figures, AXGN's net income swung from a $19.6M loss in 2026Q1 to a $2.3M profit in 2026Q3, with EPS growth figures distorted by near-zero prior-period bases, limiting the reliability of year-over-year earnings comparisons.

The magnitude of the 2026Q1 net loss relative to its operating loss suggests non-operating or tax-related items may have contributed, though the data alone cannot confirm this. Stock-based compensation of $6.8M to $16.6M per quarter is a significant reconciling item and may mask the economic cash cost of operations. Earnings quality is therefore best assessed on operating income and cash flow rather than headline EPS.

Growth Without Profit Raises Dilution Questions

According to recent SEC filings, AXGN has reported negative operating margins in most recent quarters while growing revenue above 20%, and the bear case would question whether this growth is being bought with heavy SG&A spending and stock-based compensation.

If operating losses persist while SBC remains elevated, the company may continue relying on equity or external capital to fund operations, a scenario the reported income statement alone cannot rule out. Short-sellers would likely argue that the recent positive quarter reflects timing rather than durable leverage. Investors should monitor whether the company can sustain profitability without material reliance on non-operating support.

AXGN — Frequently Asked Questions

Quick answers to the most common questions about buying AXGN stock.

What was AxoGen, Inc.'s (AXGN) revenue in 2025?

For fiscal year 2025, AxoGen, Inc. (AXGN) reported total revenue of $225.2M. This represents a 1619.1% increase compared to $13.1M in 1996.

Is AxoGen, Inc. (AXGN) profitable?

AxoGen, Inc. (AXGN) reported a net loss of $15.7M for the fiscal year ending 2025.

What is AxoGen, Inc.'s operating profit margin?

AxoGen, Inc. (AXGN) reported an operating income of $-7.8M, resulting in an operating profit margin of -3.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is AxoGen, Inc.'s gross profit and gross margin?

AxoGen, Inc. (AXGN) generated $167.4M in gross profit for the year, representing a gross profit margin of 74.3%. This demonstrates the company's core pricing power and production efficiency.